sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Patient Information Leaflet last updated on the eMC: 23/02/2011
PIL Xatral

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23/02/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change of contra-indications
  • Change to instructions about overdose
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
Updated on 30/01/2009 and displayed until 23/02/2011
Reasons for adding or updating:
  • Change to side-effects
Updated on 14/07/2008 and displayed until 30/01/2009
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 14/09/2007 and displayed until 14/07/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Pending awaiting re-submission
Updated on 14/09/2007 and displayed until 14/09/2007
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 18/11/2005 and displayed until 14/09/2007
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 18/10/2002 and displayed until 18/11/2005
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Active Ingredients/Generics

 
   alfuzosin hydrochloride